ReviewNature reviews. Immunology2014
Dendritic cell-targeted vaccines--hope or hype?
Review in Nature reviews. Immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed.
- Enhanced Transdermal Immunization via Solid-in-Oil Nanodispersions Incorporating Dendritic Cell-Targeting Peptide.Molecules (Basel, Switzerland) · 2026Article
- Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures.Molecules (Basel, Switzerland) · 2026Review
- Crosslinked ionizable lipids reprogram dendritic cell metabolism for potent mRNA vaccination.Nature materials · 2026Article
- Dendritic cells in cancer immunotherapy: functional barriers, reprogramming strategies and translational challenges.Frontiers in immunology · 2026Review
- Development of a dendritic cell-targeted vaccine strategy using proximity-induced conjugation.Theranostics · 2026Article
- Biomimetic phosphorus dendrimer multi-epitope nanovaccine enhances humoral and cellular immune response against African swine fever virus.Journal of nanobiotechnology · 2025Article
- Article
- Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers.Nature biomedical engineering · 2025Article
- CD40 Ligand Potentiates Immunogenecity ofCurrent issues in molecular biology · 2025Article
- Review
- Dendritic cell-based immunotherapy for head and neck squamous cell carcinoma: advances and challenges.Frontiers in immunology · 2025Review
- Advanced technologies for the development of infectious disease vaccines.Nature reviews. Drug discovery · 2024Review
- Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity.ACS nano · 2024Article
- A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications.Molecular therapy. Methods & clinical development · 2024Article
- Dendritic cell-targeted delivery of antigens using extracellular vesicles for anti-cancer immunotherapy.Cell proliferation · 2024Article
- SMART-lipid nanoparticles enabled mRNA vaccine elicits cross-reactive humoral responses against the omicron sub-variants.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Glycan-costumed virus-like particles promote type 1 anti-tumor immunity.bioRxiv : the preprint server for biology · 2024Article
- Enhancing cell-mediated immunity through dendritic cell activation: the role of Tri-GalNAc-modified PLGA-PEG nanoparticles encapsulating SR717.Frontiers in immunology · 2024Article
- Machine-learning and combined analysis of single-cell and bulk-RNA sequencing identified a DC gene signature to predict prognosis and immunotherapy response for patients with lung adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- Recombinant antigen delivery to dendritic cells as a way to improve vaccine design.Experimental biology and medicine (Maywood, N.J.) · 2023Review
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of an effective vaccine that elicits a strong and durable T cell response against intracellular pathogens and cancer is a challenge. One strategy to enhance the effectiveness of vaccination is by targeting dendritic cells (DCs). In this Opinion article, we discuss existing DC-targeting approaches that induce adaptive immunity. We highlight the crucial issues that need to be addressed to move the field forward and discuss whether targeting DCs could be better than current vaccine approaches.
Indexed as
Identifiers
25190285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.